Besides the high potency of erdafitinib against mUC, several recent studies have demonstrated its “off-target” effect in sensitizing cancer cells to certain chemotherapies, due to its ability to interact with ABCB1 and impair its function. The gene discussed is ABCB1; the disease is cancer.